155
Participants
Start Date
March 9, 2023
Primary Completion Date
November 16, 2024
Study Completion Date
November 16, 2024
Oral semaglutide
Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Master Centre for Israel, Kfar Saba
Lead Sponsor
Novo Nordisk A/S
INDUSTRY